Stopped Wegovy for a Month — What Happens Next?

Semaglutide's half-life is approximately one week, so its appetite-suppressing effects diminish over several weeks after stopping, not instantly.
STEP 1 trial follow-up data showed that participants who stopped semaglutide regained a significant proportion of lost weight within one year of discontinuation.
A one-month break is enough time for hunger signals to increase noticeably, but the extent of weight change varies considerably between individuals.
Restarting after a break may require returning to a lower dose; your prescriber decides the right entry point based on how long you have been off treatment.

If you have stopped Wegovy for a month, the clinical evidence is consistent: appetite tends to return, weight can begin to come back, and the hormonal effects that made the medicine work start to fade within weeks of the final dose. Semaglutide has a half-life of roughly one week, so meaningful biological activity diminishes over three to four weeks after stopping. That is not a reason for alarm — it is a reason to have a plan. Whether a pause was deliberate, forced by supply issues, a holiday, or a bout of illness, what matters now is understanding what the evidence suggests, and what options are open to you through clinical review. These are prescription-only medicines, and any decision about restarting, switching, or stopping permanently should sit with a prescriber who knows your full history.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the clinical evidence and official guidance tell you about a one-month break from Wegovy

What the STEP 1 trial data showed about stopping semaglutide

The clearest picture of what happens after discontinuation comes from the STEP 1 extension study. In the main trial, adults with obesity taking semaglutide 2.4mg lost around 15% of body weight over 68 weeks on average, as published in the New England Journal of Medicine (STEP 1, 2021). When a subset of participants stopped the medicine at week 68 and were followed for a further year, roughly two-thirds of the weight lost was regained by week 120. Hunger scores rose, and the metabolic improvements achieved during treatment (including reductions in waist circumference and blood pressure) also partially reversed.

One month is a short window in that timeline, but it is not clinically insignificant. GLP-1 receptor agonists work partly by slowing gastric emptying and reducing appetite signals in the brain; when the medicine clears, those pathways resume their usual activity. For many people, the first sign is a noticeable return of hunger within two to three weeks of stopping. Some people also find that foods they previously found unappealing become appealing again. None of this is a moral failure, it is the underlying biology reasserting itself.

The evidence does not suggest that a planned, short break causes lasting harm to treatment outcomes, particularly if diet and activity habits established during treatment are maintained. But it does underline why semaglutide is described by NICE and the NHS as a long-term medicine rather than a short course. If you are curious about whether a planned break is clinically reasonable for your situation, that question has a longer answer worth reading.

Why appetite comes back, and what changes inside the body during a break

Semaglutide mimics a gut hormone called GLP-1, which is released after eating. By activating GLP-1 receptors in the gut and brain, it slows how quickly food leaves the stomach and sends satiety signals that reduce the urge to eat. Once the last dose clears, that artificial signal disappears. The NHS patient information for semaglutide explains that the medicine works alongside a reduced-calorie diet and increased activity, emphasising that the lifestyle context matters, especially when the medicine is not present.

Gastric emptying returns to its previous speed. Hunger hormones, including ghrelin, resume their normal patterns. People who have been on Wegovy for several months often describe the experience of stopping as a switch being flipped: portion sizes that felt natural on treatment suddenly feel insufficient, and the mental quietness around food (what some call the absence of food noise) gives way to more frequent thoughts about eating.

This is worth knowing about before a break happens, not after. If a break was unplanned, perhaps because of supply difficulties or illness, the practical steps are the same: keep to the dietary patterns that were working, stay well-hydrated, and contact your prescriber about when and how to restart. There is useful detail on what to do immediately after stopping Wegovy if you need a practical walkthrough.

Restarting Wegovy after a one-month gap: what prescribers typically consider

A month off Wegovy is long enough that most prescribers will want to review your dose before restarting at the level you were on. The SmPC for semaglutide, held on the Electronic Medicines Compendium (eMC), is the reference point for re-initiation guidance, and it specifies titration steps that exist for good reason, reintroducing a higher dose after a break can increase the likelihood of gastrointestinal side effects.

In practice, if you were stable on, say, the 1.7mg or 2.4mg maintenance dose before the break, a prescriber may bring you back to a lower dose for four weeks to allow your system to readjust. If you were only partway through titration when you stopped, the re-entry point may be lower still. The prescriber also weighs how much weight has been regained, your current health picture, and whether any circumstances have changed that affect suitability. That is why restarting is a clinical decision, not simply a question of picking up where you left off.

If weight loss had plateaued before the break, a restart conversation is also a good moment to explore whether anything in your approach needs adjusting. There is a separate discussion worth having if you feel Wegovy stopped working before you paused, the cause may be different from a simple break-related rebound. Some people also find it helpful to look at why weight loss on Wegovy can plateau even during continuous treatment, and if the scale had already stalled before you stopped, it is worth reading about what to do when you have stopped losing weight on Wegovy to understand whether the break itself is the main factor.

On the cost side, if the break has prompted questions about whether continuing is affordable, Wegovy pricing for private treatment in the UK is laid out on that page, worth reading before making a financial decision that affects your health. The important thing is that a pause does not close any doors. Most people can restart safely under clinical supervision, often without significant long-term disruption to their progress.

Getting clinical support, and what nume's process looks like if you want to restart

If you paused Wegovy and are now wondering about next steps, the most useful thing you can do is speak to a prescriber. At nume, every consultation (including for people transferring from another provider or restarting after a break) is read the same day by a GPhC-registered Independent Prescriber. Not software, not a form that auto-approves. A person reads it. Evidence of your previous treatment and current position helps; you may be asked for your most recent weight and any clinical records. Our clinical team can then advise on the right re-entry dose and titration schedule for your situation.

Orders placed before 12pm on a working day are dispatched the same day once approved, arriving via tracked DPD delivery the next working day. If you have been out of the routine for a month, that kind of structure (knowing your pen arrives tomorrow, fits in the fridge door, and your prescriber has reviewed everything) makes restarting feel less daunting. You can explore the full range of weight-loss treatment options or, if you are already decided, start your free consultation there and get a clinical view on restarting today.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions